ELTX sells 4.38M shares in a registered direct offering, drawing new institutional investors amid a 5% stock decline.
Elicio Therapeutics priced a $15M registered direct offering, led by two new institutional investors and including participation from an existing shareholder. The clinical-stage biotech firm will sell approximately 4.38M shares of common stock.
The offering follows a 5% drop in ELTX shares prior to the announcement. No prior consensus or comparable offering size was disclosed for context.
The stock’s decline suggests investor caution amid the capital raise, though details on immediate market reaction remain limited.